Meet Our Team

Tim Gutwald

Partner
Connect on LinkedIn 

Tim Gutwald is a solutions-oriented attorney who helps healthcare companies grow with confidence while navigating complex legal and regulatory landscapes. As a Partner at Elevare Law, he specializes in telemedicine, virtual behavioral health, digital health, and direct-to-consumer care, guiding founders and operators through multi-state expansion and compliance.

Tim brings a rare combination of in-house leadership and firm experience. As a former General Counsel and Chief Compliance Officer for several health tech companies, he understands firsthand how legal guidance impacts day-to-day operations and growth strategy. His background in litigation also equips him to handle employment matters, contract and payor disputes, regulatory investigations and risk mitigation with an eye toward both prevention and resolution.

He brings deep expertise in privacy, security, HIPAA, and tracking technologies, having worked with clients ranging from early-stage startups to national health systems. Before joining Elevare, he helped a telepsychiatry company  scale its presence from 12 to 40+ states with a 20x increase in revenue. 

Clients trust Tim not just for his sharp legal mind, but for his ability to make complex issues feel manageable - and to show up like part of the team when it counts most. Clients appreciate that Tim provides clear, straightforward advice and works with them to find creative solutions to problems instead of saying “no.”

Tim earned his law degree from Michigan State University College of Law (magna cum laude) and holds an undergraduate degree from Kalamazoo College.

Based in Grand Rapids, Michigan, Tim lives with his wife, five children, a dog, and a cat. Outside of work, you can find him coaching youth sports, cheering on his favorite soccer teams ("Come on United!"), watching medical dramas, and reading history and philosophy books.

Licensed In: Michigan

Check out these blogs written by 

Tim Gutwald

Legal + Regulatory
October 10, 2025
The FDA Puts Telehealth Platforms and GLP-1 Advertisers on Notice
Reminiscent of the FTC’s actions around online tracking technologies, on September 9, 2025, the FDA sent hundreds of warning letters to pharmaceutical companies, compounding pharmacies, and telehealth providers. The FTC letters were quickly followed by enforcement actions against telehealth providers like Betterhelp and Cerebral, and multimillion-dollar settlements. While it remains to be seen what, if any, actions the FDA will take next, pharmacies and telehealth companies, especially those marketing GLP-1 drugs, should change how they talk about prescription drugs on their websites and social media pages and in advertisements. 
Legal + Regulatory
October 3, 2025
The Government Shutdown: What Telehealth Providers Need to Know
The federal government shut down on October 1, 2025, after lawmakers failed to reach a funding agreement.